Scientists, Advocates Voice Objections To von Eschenbach’s Conflicts, 2015.
Cancer Leadership Council Letter Calls For Permanent Leadership of NCI and FDA.
Cancer Center Directors to Develop Blueprint for Progress That’s “Honest,” M.D. Anderson’s John Mendelsohn Says.
Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help